肝细胞癌患者肝移植术后肿瘤复发转移的防治

季茹; 窦科峰; 许辉

doi:10.3969/j.issn.1001-5256.2014.01.003

肝细胞癌患者肝移植术后肿瘤复发转移的防治

DOI: 10.3969/j.issn.1001-5256.2014.01.003

1. 第四军医大学附属西京医院肝胆胰脾外科
2. 解放军第四二二医院肝胆外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3287
- HTML全文浏览量: 16
- PDF下载量: 645
- 被引次数: 0
出版历程
- 收稿日期: 2013-11-22
- 出版日期: 2014-01-20

Prevention and management of recurrence and metastasis of hepatocellular carcinoma after liver transplantation

Department of Hepatobiliary & Pancreas Surgery, Xijing Hospital, Fourth Military Medical University

摘要

摘要: 肝细胞癌(HCC)仍是目前发病率较高的消化道肿瘤,肝移植能从根本上切除肿瘤病灶,是HCC综合治疗方案中的主要手段之一。移植后肿瘤的复发和转移问题,是影响受体长期生存的主要因素。近年来,得益于全球范围的技术改进和经验积累,在HCC的诊疗方面取得了的长足的发展和进步。针对HCC肝移植适应证、复发转移预测、肝移植围手术期干预和术后HCC复发的综合治疗等方面进行探讨。
- 癌,肝细胞 /
- 肝移植 /
- 肿瘤复发,局部 /
- 肿瘤转移
Abstract: Hepatocellular carcinoma ( HCC) is still a prevalent gastrointestinal cancer. Liver transplantation ( LT) is one of the main means in the comprehensive treatment of HCC because it radically removes the tumor. However, tumor recurrence and metastasis after LT remain the main obstacles to long- term survival. In recent years, substantial progress has been made in the diagnosis and treatment of HCC thanks to the technological improvement and experience accumulation worldwide. The HCC indications for LT, prediction of HCC recurrence and metastasis, perioperative management in LT, and comprehensive treatment of recurrent HCC after LT are reviewed.
- carcinoma, hepatocellular /
- liver transplantation /
- neoplasm recurrence, local /
- neoplasm metastasis

HTML全文

参考文献(29)

[1] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]Chinese Society of Liver Cancer, Chinese Anti-Cancer Association;Chinese Society of Clinical Oncology, Chinese Anti-Cancer Association;Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association.Expert consensus on standardization of the management of primary liver cancer[J].J Clin Hepatol, 2009, 25 (2) :83-92. (in Chinese) 中国抗癌协会肝癌专业委员会;中国抗癌协会临床肿瘤学协作专业委员会;中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志, 2009, 25 (2) :83-92.

[3]HOLLEBECQUE A, DECAENS T, BOLESLAWSKI E, et al.Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation[J].Gastroenterol Clin Biol, 2009, 33 (5) :361-369.

[4]PENG CH, CHEN H.Strategy for prevention and treatment of recurrent hepatocellular carcinoma after liver transplantation[J].Natl Med J China, 2011, 91 (22) :1513-1515. (in Chinese) 彭承宏, 陈皓.肝细胞癌肝移植术后复发的防治策略[J].中华医学杂志, 2011, 91 (22) :1513-1515.

[5]SCHREIBMAN IR, BEJARANO P, MARTINEZ EJ, et al.Very late recurrence of hepatocellular carcinoma after liver transplantation:case report and literature review[J].Transplant Proc, 2006, 38 (9) :3140-3143.

[6]ROAYAIE S, SCHWARTZ JD, SUNG MW, et al.Recurrence of hepatocellular carcinoma after liver transplant:patterns and prognosis[J].Liver Transpl, 2004, 10 (4) :534-540.

[7]MELLOUL E, LESURTEL M, CARR BI, et al.Developments in liver transplantation for hepatocellular carcinoma[J].Semin Oncol, 2012, 39 (4) :510-521.

[8]CHOK KS, CHAN SC, CHEUNG TT, et al.Late recurrence of hepatocellular carcinoma after liver transplantation[J].World J Surg, 2011, 35 (9) :2058-2062.

[9]YOON YC, HONG TH, YOU YK, et al.Clinical analysis of recurrent hepatocellular carcinoma after living donor liver transplantation[J].Clin Transplant, 2013, 27 (2) :e192-e198.

[10]SHAO CK, ZHOU J, FENG ZY, et al.Influential factors for recurrence and prognosis of hepatocellular carcinoma after liver transplantation[J].Chin J Organ Transplant, 2007, 28 (12) :712-715. (in Chinese) 邵春奎, 周静, 冯智英, 等.影响肝细胞癌患者肝移植后肿瘤复发及预后的相关因素[J].中华器官移植杂志, 2007, 28 (12) :712-715.

[11]WU C, SHAN H.Analysis of risk factors for recurrence of hepatocellular carcinoma after liver transplantation[J].Natl Med J China, 2012, 92 (29) :2023-2027. (in Chinese) 吴春, 单鸿.肝细胞癌患者肝移植术后肿瘤复发的多因素分析[J].中华医学杂志, 2012, 92 (29) :2023-2027.

[12]ADLER M, de PAUW F, VEREERSTRAETEN P, et al.Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system[J].Liver Transpl, 2008, 14 (4) :526-533.

[13]SOTIROPOULOS GC, MALAGO M, MOLMENTI E, et al.Liver transplantation for hepatocellular carcinoma in cirrhosis:is clinical tumor classification before transplantation realistic?[J].Transplantation, 2005, 79 (4) :483-487.

[14]ZHOU J, FAN J, WANG Z, et al.Strategies to improve the efficacy of liver transplantation for hepatocellular carcinoma[J].Chin J Dig Surg, 2011, 10 (4) :253-255. (in Chinese) 周俭, 樊嘉, 王征, 等.提高肝癌肝移植疗效的策略[J].中华消化外科杂志, 2011, 10 (4) :253-255.

[15]LIANG YB, GENG L.Ideas about current situation of liver transplantation for liver cancer and prevention of postoperative recurrence[J].Natl Med J China, 2011, 91 (22) :1516-1518. (in Chinese) 梁廷波, 耿磊.对肝癌肝移植现状和复发防治的思考[J].中华医学杂志, 2011, 91 (22) :1516-1518.

[16]MOTOMURA T, SHIRABE K, MANO Y, et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol, 2013, 58 (1) :58-64.

[17]HALAZUN KJ, HARDY MA, RANA AA, et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J].Ann Surg, 2009, 250 (1) :141-151.

[18]WANG GY, LI H, ZHANG Q, et al.A preoperative prognostic score model to predict recurrence of hepatocellularcarcinoma following liver transplantation[J].Chin J Hepatobiliary surg, 2012, 18 (5) :325-329. (in Chinese) 汪国营, 李华, 张琪, 等.一种预测肝癌肝移植术后肿瘤复发的术前评分模型[J].中华肝胆外科杂志, 2012, 18 (5) :325-329.

[19]DAI Z, FAN J, ZHOU J, et al.Identification and network analysis of tumor recurrence-related proteins after liver transplantation for hepatocellular carcinoma[J].Chin J Hepatobiliary surg, 2011, 17 (12) :969-973. (in Chinese) 代智, 樊嘉, 周俭, 等.肝癌肝移植术后肿瘤复发相关蛋白的鉴定及生物信息学分析[J].中华肝胆外科杂志, 2011, 17 (12) :969-973.

[20]MAZZAFERRO V, BATTISTON C, PERRONE S, et al.Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation:a prospective study[J].Ann Surg, 2004, 240 (5) :900-909.

[21]CLAVIEN PA, LESURTEL M, BOSSUYT PM, et al.Recommendations for liver transplantation for hepatocellular carcinoma:an international consensus conference report[J].Lancet Oncol, 2012, 13 (1) :e11-e22.

[22]SOLL C, CLAVIEN PA.Inhibition of mammalian target of rapamycin:two goals with one shot?[J].J Hepatol, 2011, 54 (1) :182-183.

[23]TOSO C, MERANI S, BIGAM DL, et al.Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J].Hepatology, 2010, 51 (4) :1237-1243.

[24]ZIMMERMAN MA, TROTTER JF, WACHS M, et al.Sirolimusbased immunosuppression following liver transplantation for hepatocellular carcinoma[J].Liver Transpl, 2008, 14 (5) :633-638.

[25]TAKAHARA T, NITTA H, HASEGAWA Y, et al.Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor:two case reports[J].Transplant Proc, 2011, 43 (7) :2800-2805.

[26]STAUFER K, FISCHER L, SEEGERS B, et al.High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation[J].Transpl Int, 2012, 25 (11) :1158-1164.

[27]XU J, SHEN ZY, CHEN XG, et al.A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J].Hepatology, 2007, 45 (2) :269-276.

[28]BATES MJ, FARKAS E, TAYLOR D, et al.Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation[J].Ann Thorac Surg, 2008, 85 (2) :412-415.

[29]LEE JO, KIM DY, LIM JH, et al.Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation[J].J Gastroenterol Hepatol, 2009, 24 (5) :800-805.

施引文献

资源附件(0)

访问统计